<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01527292</url>
  </required_header>
  <id_info>
    <org_study_id>BCC-RAD-11-01</org_study_id>
    <nct_id>NCT01527292</nct_id>
  </id_info>
  <brief_title>Phase II Trial of Stereotactic Radiation Therapy (SRT) Versus SRT Plus Vertebral Augmentation Procedure (VAP) for Vertebral Metastasis</brief_title>
  <official_title>Randomized Phase II Trial of Stereotactic Radiation Therapy (SRT) Versus SRT Plus Vertebral Augmentation Procedure (VAP) for Vertebral Metastasis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>James Graham Brown Cancer Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>University of Louisville</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>James Graham Brown Cancer Center</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine pain control rate (Percentage of patients in each
      arm that achieve pain control) at the treated site(s) at 1 month, 2-4 months and 5-6 months
      post-treatment.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Eligible Vertebral Metastatic Lesion/s-&gt; randomized-&gt; SRT versus SRT+ VAP Stereotactic
      Radiation Therapy(SRT): 16 Gy X 1 Evaluation: prior to treatment; 1 month, 2-4 months, 5-6
      months and 1 year post-treatment
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    Unable to enroll
  </why_stopped>
  <start_date type="Actual">February 2012</start_date>
  <completion_date type="Actual">September 2, 2015</completion_date>
  <primary_completion_date type="Actual">May 2, 2015</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Numerical Rating Pain Scale (NRPS) Change in Patients</measure>
    <time_frame>For 6 months post treatment</time_frame>
    <description>To determine pain control rate (Percentage of patients in each arm that achieve pain control) at the treated site(s)at 1 month, 2-4 months and 5-6 months post-treatment and to validate of the movement-related pain score</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Reduction of Pain Estimate</measure>
    <time_frame>For 1 year post treatment</time_frame>
    <description>To estimate the relative quantitative reduction of pain from baseline in patients in each arm.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality of Life Estimate</measure>
    <time_frame>For 1 year post treatment</time_frame>
    <description>To estimate the quality of life using the Oswestry Disability Questionnaire</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Feasibility Rate Estimation</measure>
    <time_frame>For 1 year post treatment</time_frame>
    <description>To estimate the feasibility rate of the study procedure (the percentage of patients in overall and each arm that complete the treatment).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Toxicity Rate Estimation</measure>
    <time_frame>For 1 year post treatment</time_frame>
    <description>To estimate the toxicities of the treatment</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Vertebra Measurement</measure>
    <time_frame>For 1 year post treatment</time_frame>
    <description>To measure the dimensions of the treated vertebra(e) at 1 year</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">3</enrollment>
  <condition>Vertebral Metastasis</condition>
  <arm_group>
    <arm_group_label>Control Group</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Baseline Assessments and followup assessments are the same for both arms. Control group Intervention: Stereotactic Radiation Therapy only</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Treatment Group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Baseline Assessments and followup assessments are the same for both arms. Treatment group Intervention: Stereotactic Radiation Therapy with Vertebral Augmentation Procedure</description>
  </arm_group>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>Stereotactic Radiation Therapy</intervention_name>
    <description>SRT only</description>
    <arm_group_label>Control Group</arm_group_label>
    <other_name>Stereotactic Radiosurgery</other_name>
  </intervention>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>SRT with Vertebral Augmentation Procedure</intervention_name>
    <description>SRT with VAP</description>
    <arm_group_label>Treatment Group</arm_group_label>
    <other_name>Stereotactic Radiosurgery with VAP</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Age ≥ 18 years.

          2. ECOG performance status 0-1.

          3. Known histologically proven malignancy.

          4. Localized osteolytic spine metastases from T7 to L5 demonstrated by MRI, CT, PET or
             bone scan: a solitary spine metastasis; two separate spine levels; or up to 3 separate
             sites (each site may have a maximal involvement of 2 contiguous vertebral bodies with
             or without a paraspinal mass of no more than 5 cm).

          5. Negative serum pregnancy test within 2 weeks prior to registration for women of
             childbearing potential.

          6. Women of childbearing potential and male participants who are sexually active must
             agree to use a medically effective means of birth control.

          7. Numerical Rating Pain Scale (NRPS) and movement-related pain score(MRPS) within two
             (2) weeks prior to registration.

          8. The patient must have a score of ≥ 5 for at least one of the planned sites for SRT.

          9. Patients must provide study specific informed consent prior to study entry.

         10. Required Pre-treatment Evaluations: baseline Numerical Rating Pain Scale (NRPS),
             movement-related pain score, dose and frequency of all pain medications; QOL Measure
             using the Oswestry Disability Questionnaire, and EuroQOL(EQ-5D).

        Exclusion Criteria:

          1. Non-ambulatory patients.

          2. Frank spinal cord compression or epidural compression within 3 mm of the spinal cord.

          3. Osteoblastic vertebral metastasis.

          4. Prior radiation to the index spine.

          5. Patients with rapid neurologic decline.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Shiao Y Woo, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>James Graham Brown Cancer Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>James Graham Brown Cancer Center</name>
      <address>
        <city>Louisville</city>
        <state>Kentucky</state>
        <zip>40202</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>January 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>February 2, 2012</study_first_submitted>
  <study_first_submitted_qc>February 6, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 7, 2012</study_first_posted>
  <last_update_submitted>April 4, 2017</last_update_submitted>
  <last_update_submitted_qc>April 4, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">April 6, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Vertebral Metastasis</keyword>
  <keyword>pain control</keyword>
  <keyword>VAP</keyword>
  <keyword>SRT+VAP</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Neoplasm Metastasis</mesh_term>
    <mesh_term>Neoplasms, Second Primary</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

